p53 Mutation, Expression, and DNA Ploidy in Evolving Gliomas: Evidence for Two Pathways of Progression

Background Two lines of evidence indirectly implicate the tumor suppressor p53 (also known as TP53) gene in glioma development. First, germline mutations of the p53 gene are associated with increased susceptibility to glioma. Second, chromosome 17p deletions and p53 gene mutations are found frequent...

Full description

Saved in:
Bibliographic Details
Published in:JNCI : Journal of the National Cancer Institute 1994-07, Vol.86 (13), p.1011-1017
Main Authors: van Meyel, Donald J., Ramsay, David A., Casson, Alan G., Keeney, Michael, Chambers, Ann F., Cairncross, J. Gregory
Format: Article
Language:English
Subjects:
Adult
Aged
Astrocytoma - chemistry
Astrocytoma - genetics
Astrocytoma - pathology
Base Sequence
Biological and medical sciences
Cancer
Deoxyribonucleic acid
DNA
DNA ploidy
DNA, Neoplasm - genetics
Female
Flow Cytometry
gene expression
Genes
Genes, p53
glioma
Humans
Immunity (Disease)
Immunochemistry
Male
man
Medical research
Medical sciences
Middle Aged
Molecular Sequence Data
Mutation
Neurology
p53 gene
p53 protein
Ploidies
Polymerase Chain Reaction
Survival Analysis
tumor suppressor genes
Tumor Suppressor Protein p53 - analysis
Tumor Suppressor Protein p53 - genetics
Tumors
Tumors of the nervous system. Phacomatoses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Two lines of evidence indirectly implicate the tumor suppressor p53 (also known as TP53) gene in glioma development. First, germline mutations of the p53 gene are associated with increased susceptibility to glioma. Second, chromosome 17p deletions and p53 gene mutations are found frequently in suoradic gliomas of all malignancy stages. These observations suggest that mutations of the p53 gene may be early events in glioma development. Purpose Our purpose was to analyze 15 low-grade astrocytic gliomas that progressed to highergrade gliomas, examining the status of the p53 gene in both the initial and recurrent tumors. Also, we explored the relationships between p53 status, DNA ploidy, tumor grade, and patient survival. Methods Fifteen low-grade gliomas that recurred as tumors of higher grade 17–102 months after initial treatment (biopsy, resection, radiotherapy, or chemotherapy) were identified from hospital records of patients (eight male and seven female) aged 31–68 years. Pathologic diagnosis was re-evaluated. Polymerase chain reaction (PCR)-single-strand conformation polymorphism and DNA sequencing were perfomed on tissue samples from the initial and recurrent tumors of each patient, using oligonucleotide PCR primers directed to exons 5–9 of the p53 gene. p53 expression was determined by immunohistochemistry and DNA ploidy evaluated by DNA flow cytometry. Results Eight (53%) of fifteen tumors had p53 mutations in exons 5–9. Nine (64%) of fourteenwere immunopositive initially, and eight of these were also immunopositive at recurrence. p53 gene status was significantly associated with p53 expression in the initial tumor (P =.02), and p53 expression at initial diagnosis was significantly related to tumor pathology at recurrence (P =.03). Patients with p53 mutant tumors survived nearly twice as long as those without mutations (median survival, 61 versus 33 months; P =.031). There was no significant difference in recurrence-free survival between patients with p53 mutant and nonmutant tumors (48 versus 33 months; P =.37), but there was a significant difference in postrecurrence survival (17 versus 2 months; P =.019). Conclusion Low-grade tumors that recurred as anaplastic gliomas were characterized by p53 gene mutation, immunopositivity, and DNA nondiploidy. Low-grade tumors that recurred as glioblastomas generally had intact p53 genes and were immunonegative. These findings suggest that histologically indistinguishable, low-grade astrocytic glioma
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/86.13.1011